Steve Kreider
هذا المحتوى غير متوفر بلغتك بعد.
Steve Kreider is Executive Vice President and Chief Revenue Officer - Aesthetics and Therapeutics at Revance. His relevance to the botulinum toxin industry comes from the current commercial side of Daxxify after Crown Laboratories’ acquisition of Revance.
His role complements other Revance leadership context. Mark Foley represents the Daxxify approval-period CEO story, Nadeem Moiz represents current post-acquisition company leadership, and Kreider represents the revenue and commercialization role for Revance’s aesthetics and therapeutics businesses.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | EVP, Chief Revenue Officer - Aesthetics and Therapeutics |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company | Revance / Crown Laboratories |
| Relevant brand | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Kreider as EVP, Chief Revenue Officer - Aesthetics and Therapeutics on its current leadership page.
- Revance’s company materials describe a portfolio across aesthetics, skincare, and therapeutics.
- Daxxify remains the botulinum toxin product that links Revance’s current aesthetics and therapeutics organization to the toxin market graph.
- Revance’s current Daxxify indication language includes glabellar lines and cervical dystonia in adults.
Commercialization Context
Section titled “Commercialization Context”Kreider’s relevance is commercial rather than product-origin based. Daxxify’s development and original approval history belong to Revance Therapeutics’ public-company period, but current commercialization now sits within the post-acquisition Revance / Crown company structure.
That distinction separates three layers that are often compressed in market discussion: Daxxify as a product, Revance as the development and current operating context, and Crown Laboratories as the owner of the broader private-company group.
Activity and Public Context
Section titled “Activity and Public Context”Revance’s current public materials place aesthetics and therapeutics together in Kreider’s revenue-leadership title. That pairing matters because Daxxify is not only an aesthetic glabellar-line product; its U.S. label also includes cervical dystonia in adults.
Kreider should not be used as a source for clinical comparison claims. Commercial leadership can explain company structure and market activity, while Daxxify’s approved uses, warnings, dose language, and unit cautions belong to the prescribing information.